Daratumumab vs. Pomalidomide for the Treatment of Relapsed/Refractory Multiple Myeloma: A Cost‐effectiveness Analysis

American Journal of Hematology - United States
doi 10.1002/ajh.25372
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Cost-Effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients With Heavily Pretreated Relapsed–refractory Multiple Myeloma in the United States

Clinical Therapeutics
Pharmacology
2017English

Bendamustine, Pomalidomide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2018English

Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, and Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Carfilzomib for Relapsed or Refractory Multiple Myeloma

The Lancet Oncology
Oncology
2018English

Orphan Designation: Pomalidomide, Treatment of Multiple Myeloma

Case Medical Research
2019English

Results of an Early Access Treatment Protocol of Daratumumab in United States Patients With Relapsed or Refractory Multiple Myeloma

Cancer
Cancer ResearchOncology
2018English

Daratumumab, Bortezomib and Dexamethasone (Dvd) vs Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Castor)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Pcn173 - Cost-Effectiveness of New Triplet Combinations With Lenalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy63 - Cost by Outcomes Analysis of Novel Triple-Combination Therapies for Relapsed/Refractory Multiple Myeloma in Brazil

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy